Abstract
Hepatocellular Carcinoma (HCC) screening, including ultrasound and biomarker tests (AFP and PIVKA-II), can help early detection and improve survival. This study aimed to construct a health economic model to simulate the whole process of screening, diagnosis, treatment, and management in population at risk for HCC, and to evaluate the cost-effectiveness of screening compared with no screening in China.
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Published version (
Free)
Free) 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callMore From: Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research
Paper Title
Journal
Date
